CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal stent expansion remain key determinants of long-term clinical outcomes. Therefore, adequate lesion preparation has become a fundamental element to optimize procedural results.

The CUT-DRESS study evaluated the impact of predilation with a cutting balloon (CB) compared with conventional balloon predilation prior to implantation of the Abluminus drug-eluting stent. This was an investigator-initiated randomized study in which patients were assigned, before lesion preparation, to a predilation strategy with either CB or a conventional balloon.

A total of 96 patients with coronary lesions suitable for treatment with the Abluminus stent were included. Patients with STEMI, left main coronary artery lesions, arterial or venous bypass grafts, chronic total occlusions (CTO), and complex in-stent restenosis were excluded.

The primary endpoints were post-procedural minimum stent area (MSA) and the percentage of neointimal hyperplasia at 9 months.

In the angiographic analysis, no significant differences were observed between the lesion preparation strategies. The MSA was 4.81 mm² in the conventional balloon group versus 5.92 mm² in the CB group, without reaching statistical significance (p=0.06).

Similarly, the percentage of neointimal hyperplasia at 9 months was comparable between both groups (12.7% vs 11.1%; p=0.188).

Read also: CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty.

Regarding the clinical outcomes at one year, the incidence of events was low and no significant differences were observed between the two strategies.

The CUT-DRESS study demonstrated that predilation with a CB before implantation of the Abluminus stent was not associated with a significant improvement in MSA or neointimal hyperplasia.

Presented by Jorge Sanz Sánchez in the Late Breaking Clinical Trials, CRT 2026, Washington, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...